Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss in Head and Neck Cancer
NCT04915183Phase 2Recruiting
- Sponsor
- National Institute on Deafness and Other Communication Disorders
- Start
- Jul 2024
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hearing loss comparing Atorvastatin (40 mg) with Placebo (2 arms). Primary endpoint: Incidence of Hearing Loss according to CTCAEv5.0 Grade >=2 criteria. Started Jul 2024; status: recruiting.
02
Drugs
atorvastatin
03
Conditions
hearing loss
Beyond the preview
Go deeper on NCT04915183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04915183.